Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis

Daniel O. Clegg; Domenic J. Reda; Edwin Mejias; Grant W. Cannon; Michael H. Weisman; Thomas Taylor; Elly Budiman-Mak; Warren D. Blackburn; Frank B. Vasey; Maren L. Mahowald; John J. Cush; H. Ralph Schumacher; Stuart L. Silverman; F. Paul Alepa; Michael E. Luggen; Miriam R. Cohen; Rama Makkena; Clair M. Haakenson; Richard H. Ward; B. J. Manaster; Robert J. Anderson; John R. Ward; William G. Henderson

doi:10.1002/art.1780391210

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis

Daniel O. Clegg, Domenic J. Reda, Edwin Mejias, Grant W. Cannon, Michael H. Weisman, Thomas Taylor, Elly Budiman-Mak, Warren D. Blackburn, Frank B. Vasey, Maren L. Mahowald, John J. Cush, H. Ralph Schumacher, Stuart L. Silverman, F. Paul Alepa, Michael E. Luggen, Miriam R. Cohen, Rama Makkena, Clair M. Haakenson, Richard H. Ward, B. J. ManasterRobert J. Anderson, John R. Ward, William G. Henderson

Research output: Contribution to journal › Review article › peer-review

441 Scopus citations

Abstract

Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory drug therapy. Methods. Two hundred twenty-one patients with PsA were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on joint pain/ tenderness and swelling scores and physician and patient global assessments. Results. Longitudinal analysis revealed a trend favoring SSZ treatment (P = 0.13). At the end of treatment, response rates were 57.8% for SSZ compared with 44.6% for placebo (P = 0.05). The Westergren erythrocyte sedimentation rate declined more in the PsA patients taking SSZ than in those taking placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints, including dyspepsia, nausea, vomiting, and diarrhea. Conclusion. SSZ at a dosage of 2,000 mg/day is well tolerated and may be more effective than placebo in the treatment of patients with PsA.

Original language	English (US)
Pages (from-to)	2013-2020
Number of pages	8
Journal	Arthritis and rheumatism
Volume	39
Issue number	12
DOIs	https://doi.org/10.1002/art.1780391210
State	Published - Dec 1996
Externally published	Yes

ASJC Scopus subject areas

Immunology and Allergy
Rheumatology
Immunology
Pharmacology (medical)

Access to Document

10.1002/art.1780391210

Cite this

Clegg, D. O., Reda, D. J., Mejias, E., Cannon, G. W., Weisman, M. H., Taylor, T., Budiman-Mak, E., Blackburn, W. D., Vasey, F. B., Mahowald, M. L., Cush, J. J., Schumacher, H. R., Silverman, S. L., Alepa, F. P., Luggen, M. E., Cohen, M. R., Makkena, R., Haakenson, C. M., Ward, R. H., ... Henderson, W. G. (1996). Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. Arthritis and rheumatism, 39(12), 2013-2020. https://doi.org/10.1002/art.1780391210

Clegg, DO, Reda, DJ, Mejias, E, Cannon, GW, Weisman, MH, Taylor, T, Budiman-Mak, E, Blackburn, WD, Vasey, FB, Mahowald, ML, Cush, JJ, Schumacher, HR, Silverman, SL, Alepa, FP, Luggen, ME, Cohen, MR, Makkena, R, Haakenson, CM, Ward, RH, Manaster, BJ, Anderson, RJ, Ward, JR & Henderson, WG 1996, 'Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis', Arthritis and rheumatism, vol. 39, no. 12, pp. 2013-2020. https://doi.org/10.1002/art.1780391210

@article{d87d2c8a8164434f90c6621a698423fc,

title = "Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis",

abstract = "Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory drug therapy. Methods. Two hundred twenty-one patients with PsA were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on joint pain/ tenderness and swelling scores and physician and patient global assessments. Results. Longitudinal analysis revealed a trend favoring SSZ treatment (P = 0.13). At the end of treatment, response rates were 57.8% for SSZ compared with 44.6% for placebo (P = 0.05). The Westergren erythrocyte sedimentation rate declined more in the PsA patients taking SSZ than in those taking placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints, including dyspepsia, nausea, vomiting, and diarrhea. Conclusion. SSZ at a dosage of 2,000 mg/day is well tolerated and may be more effective than placebo in the treatment of patients with PsA.",

author = "Clegg, {Daniel O.} and Reda, {Domenic J.} and Edwin Mejias and Cannon, {Grant W.} and Weisman, {Michael H.} and Thomas Taylor and Elly Budiman-Mak and Blackburn, {Warren D.} and Vasey, {Frank B.} and Mahowald, {Maren L.} and Cush, {John J.} and Schumacher, {H. Ralph} and Silverman, {Stuart L.} and Alepa, {F. Paul} and Luggen, {Michael E.} and Cohen, {Miriam R.} and Rama Makkena and Haakenson, {Clair M.} and Ward, {Richard H.} and Manaster, {B. J.} and Anderson, {Robert J.} and Ward, {John R.} and Henderson, {William G.}",

year = "1996",

month = dec,

doi = "10.1002/art.1780391210",

language = "English (US)",

volume = "39",

pages = "2013--2020",

journal = "Arthritis and rheumatism",

issn = "0004-3591",

publisher = "John Wiley and Sons Ltd",

number = "12",

}

TY - JOUR

T1 - Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis

AU - Clegg, Daniel O.

AU - Reda, Domenic J.

AU - Mejias, Edwin

AU - Cannon, Grant W.

AU - Weisman, Michael H.

AU - Taylor, Thomas

AU - Budiman-Mak, Elly

AU - Blackburn, Warren D.

AU - Vasey, Frank B.

AU - Mahowald, Maren L.

AU - Cush, John J.

AU - Schumacher, H. Ralph

AU - Silverman, Stuart L.

AU - Alepa, F. Paul

AU - Luggen, Michael E.

AU - Cohen, Miriam R.

AU - Makkena, Rama

AU - Haakenson, Clair M.

AU - Ward, Richard H.

AU - Manaster, B. J.

AU - Anderson, Robert J.

AU - Ward, John R.

AU - Henderson, William G.

PY - 1996/12

Y1 - 1996/12

N2 - Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory drug therapy. Methods. Two hundred twenty-one patients with PsA were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on joint pain/ tenderness and swelling scores and physician and patient global assessments. Results. Longitudinal analysis revealed a trend favoring SSZ treatment (P = 0.13). At the end of treatment, response rates were 57.8% for SSZ compared with 44.6% for placebo (P = 0.05). The Westergren erythrocyte sedimentation rate declined more in the PsA patients taking SSZ than in those taking placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints, including dyspepsia, nausea, vomiting, and diarrhea. Conclusion. SSZ at a dosage of 2,000 mg/day is well tolerated and may be more effective than placebo in the treatment of patients with PsA.

AB - Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory drug therapy. Methods. Two hundred twenty-one patients with PsA were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on joint pain/ tenderness and swelling scores and physician and patient global assessments. Results. Longitudinal analysis revealed a trend favoring SSZ treatment (P = 0.13). At the end of treatment, response rates were 57.8% for SSZ compared with 44.6% for placebo (P = 0.05). The Westergren erythrocyte sedimentation rate declined more in the PsA patients taking SSZ than in those taking placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints, including dyspepsia, nausea, vomiting, and diarrhea. Conclusion. SSZ at a dosage of 2,000 mg/day is well tolerated and may be more effective than placebo in the treatment of patients with PsA.

UR - http://www.scopus.com/inward/record.url?scp=2042519830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2042519830&partnerID=8YFLogxK

U2 - 10.1002/art.1780391210

DO - 10.1002/art.1780391210

M3 - Review article

C2 - 8961906

AN - SCOPUS:2042519830

SN - 0004-3591

VL - 39

SP - 2013

EP - 2020

JO - Arthritis and rheumatism

JF - Arthritis and rheumatism

IS - 12

ER -

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this